Crinetics Pharmaceuticals, Inc. (CRNX)

43.82 -0.18 (-0.41%) 收市：04:00PM EDT

Crinetics Pharmaceuticals, Inc.

6055 Lusk Boulevard
San Diego, CA 92121
United States
858 450 6464
https://www.crinetics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 290

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. R. Scott Struthers Ph.D.	Founder, President, CEO & Director	978.34k	5.65M	1963
Dr. Stephen F. Betz Ph.D.	Founder & Chief Scientific Officer	672.66k	無	1966
Mr. Marc J. C. Wilson	Chief Financial Officer	642.25k	408.5k	1979
Mr. Jeff E. Knight	Chief Operating Officer	657.31k	無	1971
Dr. Alan S. Krasner M.D.	Chief Endocrinologist	653.92k	125.93k	1963
Mr. James Hassard	Chief Commercial Officer	623.5k	無	1966
Ms. Garlan Adams	General Counsel & Corporate Secretary	無	無	無
Ms. Adriana Cabre M.B.A.	Chief Human Resources Officer	無	無	無
Mr. Kevin Capps	Head of Intellectual Property	無	無	無
Mr. Chris Robillard M.B.A.	Chief Business Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

公司管治

截至 2024年4月29日 止，Crinetics Pharmaceuticals, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：3；董事會：7；股東權利：8；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。